Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2023 Jul 3

PMID 37397787

Authors

Siddhartha Dutta

Rima B Shah

Shubha Singhal

Sudeshna Banerjee Dutta

Sumit Bansal

Susmita Sinha

Mainul Haque

Affiliations

Soon will be listed here.

Abstract

Metformin has been designated as one of the most crucial first-line therapeutic agents in the management of type 2 diabetes mellitus. Primarily being an antihyperglycemic agent, metformin also has a plethora of pleiotropic effects on various systems and processes. It acts majorly by activating AMPK (Adenosine Monophosphate-Activated Protein Kinase) in the cells and reducing glucose output from the liver. It also decreases advanced glycation end products and reactive oxygen species production in the endothelium apart from regulating the glucose and lipid metabolism in the cardiomyocytes, hence minimizing the cardiovascular risks. Its anticancer, antiproliferative and apoptosis-inducing effects on malignant cells might prove instrumental in the malignancy of organs like the breast, kidney, brain, ovary, lung, and endometrium. Preclinical studies have also shown some evidence of metformin's neuroprotective role in Parkinson's disease, Alzheimer's disease, multiple sclerosis and Huntington's disease. Metformin exerts its pleiotropic effects through varied pathways of intracellular signalling and exact mechanism in the majority of them remains yet to be clearly defined. This article has extensively reviewed the therapeutic benefits of metformin and the details of its mechanism for a molecule of boon in various conditions like diabetes, prediabetes, obesity, polycystic ovarian disease, metabolic derangement in HIV, various cancers and aging.

Citing Articles

Drug Repurposing and Nanotechnology for Topical Skin Cancer Treatment: Redirecting toward Targeted and Synergistic Antitumor Effects.

Martins M, Veiga F, Paiva-Santos A, Pires P ACS Pharmacol Transl Sci. 2025; 8(2):308-338.

PMID: 39974652 PMC: 11833728. DOI: 10.1021/acsptsci.4c00679.

High-Glucose-Induced Metabolic and Redox Alterations Are Distinctly Modulated by Various Antidiabetic Agents and Interventions Against FABP5/7, MITF and ANGPTL4 in Melanoma A375 Cells.

Nishikiori N, Ohguro H, Watanabe M, Higashide M, Ogawa T, Furuhashi M Int J Mol Sci. 2025; 26(3).

PMID: 39940783 PMC: 11817646. DOI: 10.3390/ijms26031014.

Recent advances in the management of knee osteoarthritis: a narrative review.

Shtroblia V, Petakh P, Kamyshna I, Halabitska I, Kamyshnyi O Front Med (Lausanne). 2025; 12:1523027.

PMID: 39906596 PMC: 11790583. DOI: 10.3389/fmed.2025.1523027.

Bibliometric analysis of metformin as an immunomodulator (2013-2024).

Zhou T, Yu Y, Li L, Liu X, Xiang Q, Yu R Front Immunol. 2025; 15():1526481.

PMID: 39845945 PMC: 11750822. DOI: 10.3389/fimmu.2024.1526481.

Research progress on quercetin in improving the survival rate of random skin flap.

Xu S, Zhang W, Zhang X Arch Dermatol Res. 2025; 317(1):267.

PMID: 39821658 DOI: 10.1007/s00403-024-03696-5.

References

Niehr F, Von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H . Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011; 9:76. PMC: 3152784. DOI: 10.1186/1479-5876-9-76. View

Lyu X, Lyu T, Wang X, Zhu H, Pan H, Wang L . The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Int J Endocrinol. 2021; 2021:6616693. PMC: 7910049. DOI: 10.1155/2021/6616693. View

Febbraro T, Lengyel E, Romero I . Old drug, new trick: repurposing metformin for gynecologic cancers?. Gynecol Oncol. 2014; 135(3):614-21. PMC: 4268303. DOI: 10.1016/j.ygyno.2014.10.011. View

Kheniser K, Kashyap S, Kasumov T . A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function. Obes Sci Pract. 2019; 5(1):36-45. PMC: 6381305. DOI: 10.1002/osp4.309. View

Cantrell L, Zhou C, Mendivil A, Malloy K, Gehrig P, Bae-Jump V . Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol. 2009; 116(1):92-8. PMC: 2789879. DOI: 10.1016/j.ygyno.2009.09.024. View

Kato Y, Koide N, Komatsu T, Tumurkhuu G, Dagvadorj J, Kato K . Metformin attenuates production of nitric oxide in response to lipopolysaccharide by inhibiting MyD88-independent pathway. Horm Metab Res. 2010; 42(9):632-6. DOI: 10.1055/s-0030-1255033. View

Wang Q, Wen Y, Li D, Xia J, Zhou C, Yan D . Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol. 2010; 29(1):77-83. DOI: 10.1007/s12032-010-9766-y. View

Gilbert C, Valois M, Koren G . Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. Fertil Steril. 2006; 86(3):658-63. DOI: 10.1016/j.fertnstert.2006.02.098. View

Niemuth N, Klaper R . Emerging wastewater contaminant metformin causes intersex and reduced fecundity in fish. Chemosphere. 2015; 135:38-45. DOI: 10.1016/j.chemosphere.2015.03.060. View

10.

Tseng C . Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan. Gynecol Oncol. 2015; 138(1):147-53. DOI: 10.1016/j.ygyno.2015.03.059. View

11.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P . The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-86. DOI: 10.1038/sj.onc.1211024. View

12.

Meric-Bernstam F, Gonzalez-Angulo A . Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27(13):2278-87. PMC: 2738634. DOI: 10.1200/JCO.2008.20.0766. View

13.

Harmooshi N, Abeshtan A, Zakerkish M, Mirmomeni G, Rahim F . The effect of metformin on body mass index and metabolic parameters in non-diabetic HIV-positive patients: a meta-analysis. J Diabetes Metab Disord. 2021; 20(2):1901-1911. PMC: 8630165. DOI: 10.1007/s40200-021-00869-1. View

14.

Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G . Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 2010; 120(7):2355-69. PMC: 2898585. DOI: 10.1172/JCI40671. View

15.

Shirasaka Y, Lee N, Zha W, Wagner D, Wang J . Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice. Drug Metab Pharmacokinet. 2016; 31(5):385-388. PMC: 5319846. DOI: 10.1016/j.dmpk.2016.04.005. View

16.

Zhang K, Yang W, Dai H, Deng Z . Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis. Diabetes Res Clin Pract. 2020; 160:108001. DOI: 10.1016/j.diabres.2020.108001. View

17.

Thakkar B, Aronis K, Vamvini M, Shields K, Mantzoros C . Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism. 2013; 62(7):922-34. DOI: 10.1016/j.metabol.2013.01.014. View

18.

Petti C, Vegetti C, Molla A, Bersani I, Cleris L, Mustard K . AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway. Melanoma Res. 2012; 22(5):341-50. DOI: 10.1097/CMR.0b013e3283544929. View

19.

Wang X, Zhang J, Li L, Zhao X, Tao H, Zhang L . Metformin improves cardiac function in rats via activation of AMP-activated protein kinase. Clin Exp Pharmacol Physiol. 2010; 38(2):94-101. DOI: 10.1111/j.1440-1681.2010.05470.x. View

20.

. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012; 35(4):731-7. PMC: 3308305. DOI: 10.2337/dc11-1299. View